TVGN · Tevogen Bio Holdings Inc.

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Tevogen.AI was built to solve a critical challenge in drug development: identifying biological targets which are most likely to work in patients, before entering costly clinical trials. Over the past year, the Company has built a proprietary database of more than 655 million peptide sequences derived from approximately 24 million proteins, representing nearly 16 billion data points across multiple disease areas. This database is continuously enriched using analysis of 37 million scientific publications. Improved Prediction Accuracy In recent beta testing of its PredicTcell™ model, Tevogen reported: Recall improved from 87% to 92% (the model is finding more of the right targets) Precision improved from 40% to 48% (fewer incorrect predictions) Higher overall

WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company’s progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489, its investigational off-the-shelf, precision T-cell therapy, to address the urgent needs of the estimated 7% of U.S. adults suffering from Long COVID. Clinical Foundation: Building on proof-of-concept data where 100% of treated high-risk patients did not develop Long COVID, Tevogen is finalizing the

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek Stobinski Generics: Sadiq Khan and David Banko Contract Research: William Keane Biotech: Lori Grosso Artificial Intelligence: Mittul Mehta About Tevogen Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages

WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time. Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of $50 million. While these discussions remain subject to customary due diligence, negotiation, and definitive agreements, we believe the opportunity aligns with our disciplined

WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines. The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience. If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including: 11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. market Multiple ANDAs currently filed with the U.S. Food and Drug Administration awaiting approval Additional generic products in development Dr. Ryan Saadi,

WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on February 19, 2026, and provided the Board with discretion to determine the final reverse stock split ratio. The reverse stock split is being conducted to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market (“Nasdaq”) and is expected to become effective at 12:01 a.m. on March 6, 2026 (the “Effective Date”). The Company’s common stock is expected to begin trading on Nasdaq on a split-adjusted basis as of the beginning of trading on March 6, 2026, under the same symbol, “TVGN”, and a new CUSIP number, 88165K 200. On the Effective Date, every 50 shares of the Company’s common stock issued and outstanding will be

WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise. Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally. We believe this combination of operational control and service revenue may strengthen earnings visibility, support a more capital-efficient growth model, and enhance patient affordability.” The proposed transaction remains subject to, among other things, completion

WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Sciometrix Inc. (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix. The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the integration of Sciometrix’s digital care management capabilities, including its Clinicus platform, and remote patient monitoring technologies, with the Tevogen.AI initiative. Tevogen believes the acquisition may: Accelerate Tevogen’s

WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Sciometrix Inc. (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix. The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the integration of Sciometrix’s digital care management capabilities, including its Clinicus platform, and remote patient monitoring technologies, with the Tevogen.AI initiative. Tevogen believes the acquisition may: Accelerate Tevogen’s

WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors after a determination that a dividend would be the best use of Company capital at the time. No assurance can be given that a dividend will be declared, nor as to the timing or amount of any such dividend. Further updates will be provided as appropriate and in accordance with applicable disclosure

WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ryan Saadi, commented, “Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.” About Tevogen Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of

Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) - Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, and advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities. Platform Scalability and Manufacturing Readiness: Tevogen reported enhancements to ExacTcell™ that increased laboratory yields of target-specific CTLs per product, supporting improved consistency and throughput. These improvements are intended to enable efficient clinical supply and support future